Announcements Trials
Browse Landscape

Phase

Phase NA 19Phase 2 11Phase 1 11Phase 3 9Phase 1/2 4Phase 2/3 3Phase EARLY_PHASE1 2

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 117Neoplasms 101Prostatic Neoplasms 76Carcinoma, Non-Small-Cell Lung 75Colorectal Neoplasms 73Carcinoma, Hepatocellular 67Leukemia, Myeloid, Acute 59Stomach Neoplasms 52Neoplasm Metastasis 50Lung Neoplasms 48Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Pancreatic Neoplasms 40Recurrence 36Head and Neck Neoplasms 32Rectal Neoplasms 30Colonic Neoplasms 30Leukemia 29Multiple Myeloma 28Ovarian Neoplasms 26Lymphoma 25Squamous Cell Carcinoma of Head and Neck 24Hematologic Neoplasms 23Melanoma 22Urinary Bladder Neoplasms 20Liver Neoplasms 20Polycystic Ovary Syndrome 19Myelodysplastic Syndromes 19Lymphoma, Large B-Cell, Diffuse 19Esophageal Neoplasms 19Uterine Cervical Neoplasms 16

Interventions

valrubicin 2Oncolytic Virotherapy 1Mitomycin 1Interferons 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Carcinoma in Situ × Clear all
NCT01438112 2021-04-14

BOND

CG Oncology, Inc.

Phase 2/3 Terminated
22 enrolled
Genitourinary

Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Virus Diseases

NCT00406068 2016-07-28

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

Bioniche Life Sciences Inc.

Phase 2/3 Completed
129 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Mycobacterium Infections, Neoplasm Recurrence, Local

NCT01316874 2015-06-12

Bladder Cancer

Endo Pharmaceuticals

Phase 2/3 Completed
90 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡